ALTIMMUNE INC

ALTNASDAQ

🏆 #2154 by market capUS Equity

$3.00▼ $0.05 (−1.64%)

Live

1h—

24h▼ 1.6%

7d▼ 1.0%

14d▲ 2.6%

30d▲ 0.0%

1y▼ 16.7%

🏦Market Cap

$583M

Small Cap

📈Revenue Growth (YoY)

+80.0%

High Growth

📊Gross Margin

—

💵FCF Margin

439.0%

Strong

⚖️P/S Ratio

14294.8x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $2.98 – $3.03
52-Week Range: $2.56 – $6.44
Volume: $2.39B
Avg Volume: $1.70B
Shares Outstanding: 194.5M
Next Earnings: Sep 21, 2026

Fundamentals Snapshot

Annual Revenue: $41,000
Last Q Revenue: $11,047
P/E Ratio: —
P/S Ratio: 14294.8x
EPS (TTM): $-0.92
Dividend Yield: —

Why Investors Own ALT

✓High-growth profile — revenue up +19.9% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$41,000▲ +23.4% YoY

Gross Margin (TTM)

35.3%▲ +1.9% YoY

Operating Income (TTM)

$10,906▲ +23.4% YoY

Free Cash Flow (TTM)

$5,617▲ +23.4% YoY

About ALTIMMUNE INC

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

🦦